Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Chemotherapy with G-CSF in Burkitt Lymphoma/Leukemia
NCT00039130Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- May 2002
- Primary completion
- Sep 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in Burkitt lymphoma (BL) and Burkitt leukemia, sponsored by Cancer and Leukemia Group B. Primary endpoint: Complete Response Rate at 6 months. Started May 2002; status: completed.
02
Drugs
rituximab
03
Conditions
Burkitt lymphoma (BL)Burkitt leukemia
Beyond the preview
Go deeper on NCT00039130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039130.